Background: Gastric cancer (GC) represents a major health burden worldwide often
Introduction
Gastric cancer (GC) represents a major health burden worldwide, affecting about onemillion people per year (1), (2) . GC is often diagnosed at an advanced stage and consequently carries a poor prognosis (3) . Importantly, if it is detected at an early asymptomatic stage, it can be curable (4); e.g. in Japan, a country with the highest incidence of GC, nation-wide strategies based on improved tests for detection of early GC or precancerous lesions have decreased the incidence of GC and increased survival rate (5) .
Although GC arises from the complex interplay of environmental and host genetic factors (6, 7) , the major risk factor is Helicobacter pylori infection, which is associated with more than 80% of all distal GC cases (8) . The prevalence of H. pylori infection is high, with 80-95% of the population infected in developing countries and up to 30%-40% of adults in industrialized countries (6) . All infected individuals develop a gastritis which evolve to peptic ulcer diseases in about 10% of the cases, while gastric adenocarcinoma and mucosaassociated lymphoid tissue (MALT) lymphoma develop in <3% and 0.3% of infected subjects, respectively (9, 10) . Two types of GC can be distinguished, the intestinal and diffuse types. The intestinal type develops through progressive changes in the gastric mucosa from non-atrophic gastritis (NAG), atrophic gastritis, intestinal metaplasia (IM), dysplasia and gastric cancer (GC) (11) . It has been shown that eradication of the infection at an early stage can reverse gastric lesions and more importantly, prevent the development of preneoplasia ( (7), (12) , (13) ). A clinical study conducted in Japan demonstrated the efficacy of H. pylori eradication to reduce the incidence of GC (14) , and confirmed that it was not enough to prevent all GC cases. These data raise the need for the development of biomarkers to detect precancerous lesions or early GC; the test should be a simple and non-invasive method, applicable in large scale screening programs. In the case of intestinal type GC, the measure of pepsinogens levels has been shown to be useful to detect gastric atrophy, although its utility in non-Asian countries is controversial (15) . Thus, in spite of several efforts to develop biomarkers to identify patients at risk for distal GC (16) , no efficacious screening test is yet available.
Mitochondria are essential organelles of eukaryotic cells that possess their own genome.
Mitochondrial DNA (mtDNA) is a circular molecule present at 2-10 copies per organelle (17) .
Both, mutations and alterations of mtDNA content have been described in many different cancer types (18) (19) (20) . MtDNA mutations have been detected at early stages of gastric carcinogenesis (21, 22) . In H. pylori-infected patients, mtDNA mutations are significantly more frequent in GC patients than in cancer free patients (23) . According to our previous studies, mtDNA mutations are induced in vitro in H. pylori-infected gastric epithelial cells and in the gastric mucosa of chronically infected mice (24), (25) . A decrease in mtDNA content has also been described in most tumor tissues of advanced GC, compared with nearby non-tumor control tissue (26) , (27) , (28) . Changes in peripheral blood mtDNA levels have recently emerged as a potential preventive/diagnosis biomarker associated with cancer risk (18) . Circulating mtDNA levels were significantly higher in patients with urologic malignancies (29) , breast (30) colorectal (31) and lung cancer (32, 33) . These studies indicated that increased mtDNA content in peripheral blood is associated with elevated cancer risk. However, contrasting reports have found mtDNA depletion in the blood of patients with stage I breast tumors (34) . A recent large prospective cohort study in women from Shanghai, found no association between the leukocyte mtDNA copy number and the presence of gastric tumor (35) . However, they observed a positive association between a risk of developing GC and low mtDNA copy numbers in blood collected within the two years prior to cancer diagnosis. To our knowledge, there are no other reports on the variation of circulating mtDNA during the gastric carcinogenesis cascade, in particular comparing pre-neoplastic and neoplastic stages. To address this issue, in the present study we measured levels of mtDNA in the peripheral leucocytes of NAG, IM and GC patients. Our data showed significant variations in mtDNA levels during the progression from NAG to IM and to GC, supporting the notion that circulating mtDNA levels can be useful as potential biomarkers for the identification of early steps of gastric carcinogenesis. patients with IM and 49 with GC for a total of 126 patients recruited during the period 1999-2002. Patients from both cohorts were adults who were attended for gastroduodenal diseases at IMSS. We selected patients who were not under treatment for cancer and who had not been treated with antibiotics, bismuth compounds, proton pump inhibitors and non-steroidal antiinflammatory drugs for at least two preceding weeks. Diagnosis was based on endoscopic examination and histopathology analysis (36) . All patients and asymptomatic controls were informed and asked to sign a consent letter. The study was approved by the ethical committee from the National Council for Research on Health, IMSS.
Material and methods

Study population
Collection of clinical samples and histological analysis
For each patient, 10 ml of blood were collected and gastric tissue specimens isolated. For patients with NAG or IM, gastric biopsies collected from both the antrum and the corpus were pylori was confirmed by Giemsa staining and serology.
Circulating mtDNA
Peripheral blood (10ml) was taken from each patient, and mononuclear cells were purified by centrifugation through a Ficoll-Hypaque density gradient. DNA was isolated from these cells using the salting-out micro-technique and frozen at -70°C until tested for mtDNA quantification. The serum fraction was separated from cells and frozen at -20ºC until tested for serology to H. pylori antigens and IL-8 levels.
Determination of IgG against H. pylori antigens and of IL-8 in the serum fractions
H. pylori serology was determined with IgG antibodies against H. pylori whole-cell antigens and against CagA H. pylori protein using an enzyme-linked immune-absorbent assays (ELISA) previously validated by us (37) . Serological levels of IL-8 were measured by ELISA (BD Biosciences).
Quantification of mtDNA
MtDNA levels were measured on DNA isolated from circulating leukocytes by quantitative Polymerase Chain Reaction (q-PCR) using the StepOne TM Plus Real-Time PCR system and FastStart Universal SYBR Green Master (Applied Biosystems) as previously described (38) .
MtDNA was quantified using a region in the 12S ribosomal RNA gene, and the nuclear ΔCt as previously described (40).
Data analysis.
The Student's t-test and Pearson's chi 2 test were used to compare mtDNA level in peripheral blood between healthy subjects and patients at various stages of the gastric pathologies.
Differences were considered significant for p-values<0.05. For Odd Ratio (OR) determination the 95% confidence intervals were determined according to the Woolf's method (41) . The sensitivity and specificity of mtDNA and IL-8 tests were calculated using receiver operator characteristic (ROC) analyses. Statistical tests performed using GraphPad Prism4 for Macintosh (GraphPad Inc., La Jolla, CA).
Results
Characteristics of the studied cohorts
The general characteristics of the patients included in this study are described in Table 1 in GC. Overall, IM and GC patients were older compared to NAG patients.
Levels of mtDNA in peripheral leukocytes from patients with NAG and GC
In Cohort 1, mtDNA was quantified in NAG and GC patients as described in material and methods, and compared with asymptomatic H. pylori negative subjects. In asymptomatic controls, the relative mtDNA values ranged from 2 to 17.09, whereas in NAG group minimum and maximum mtDNA levels were 0.05 and 29.3 respectively. Even though in GC patients minimum mtDNA level was 1.74, the maximum value measured was 60 ( Figure 1A ).
Mean mtDNA levels were significantly higher in GC patients compared to asymptomatic controls (2-fold) (p-value=0.0013) and to NAG patients (2.2-fold) (p-value=0.0095). As reported in Figure 1A , three intervals of mtDNA values can be distinguished: whereas for all healthy individuals, mtDNA values grouped between 2 and 20 (interval II); in the mtDNA <2.0 group (interval I) only NAG (46% of the cases) and GC (14% of the cases) patients were observed. Importantly, samples with mtDNA<0.5 corresponded exclusively to NAG cases. In contrast, mtDNA values >20 (interval III) were not observed in healthy individuals, and only in 7% of NAG, but in 28% of GC cases. We performed a ROC analyses (42) to determine a cut-off value of mtDNA that will differentiate GC cases from the asymptomatic H. pylorinegative controls and found a value of 8.46, with a specificity of 80%, but a sensitivity of 47%. However, using this value we found that mtDNA>8. 46 
2), in agreement with an association between the presence of gastric malignancy and increased peripheral leukocytes mtDNA content.
An analysis of GC subgroups according to GC types, showed that the mean mtDNA values were similar among diffuse (n=28) and intestinal types (n=20) of GC patients, and significantly higher compared to healthy and NAG samples ( Figure 1B) . The severity of GC did not affect mtDNA as no significant differences were identified between cases with hyperplasia, metastasis or late-stage (unresectable) ( Figure 1B) . The presence of H. pylori infection had no effect on mtDNA content neither in NAG or in GC patients (Supplementary Figure S1 ). In addition, age had no influence on mtDNA levels among asymptomatic controls, NAG and GC groups, although a weak correlation was observed when considering the whole cohort (Supplementary Figure S2A) . However, no effect of age was detected on mtDNA on both healthy and NAG samples, despite the presence of old individuals (Supplementary Figure S2A , insert graph Cohort 1). Furthermore, a slight mtDNA decrease in smokers compared to non-smokers was noticed (Supplementary Figure S3A) .
In order to validate results in Cohort 1, and to further test whether mtDNA levels differentiate patients with pre-neoplasia from NAG patients, mtDNA was quantified in Cohort 2 which included patients with NAG (n=46), intestinal metaplasia (IM) (n=31) and GC (n=49) ( Table   1) peripheral leucocytes mtDNA levels shifted to higher values in GC patients as compared to pre-neoplastic NAG and IM patients. Age had no influence on mtDNA levels, in NAG, IM and GC groups, although a weak association was found for the whole cohort (p-value=0.04) (Supplementary Figure S2C) . As for Cohort 1, the same analysis including only non cancer groups did not show any effect of age on mtDNA levels, despite the advanced age of some patients in these groups, specially among IM patients for which mean age was similar to GC patients (Supplementary Figure S2C , insert graph Cohort 2).
Comparison of serological levels of IL-8 and mtDNA in NAG and GC patients
Chronic gastric inflammation is associated with the promotion of carcinogenesis and inflammation can be correlated with plasma mtDNA levels (43). We wondered whether there was any correlation between plasma IL-8 and mtDNA in patients with NAG and GC using samples from Cohort 1. IL-8 levels are not affected by parameters as age (Supplementary patients with "normal" mtDNA levels (interval II), in spite of the lack of correlation between mtDNA and IL-8 levels (Figure 3 ).
Discussion
Gastric cancer remains the second cause of death by cancer, often detected at an advanced stage. Thus, there is a real need to develop appropriate screening strategies for its early detection. In Japan, one of the countries with the highest incidence of GC, strategies that include the eradication of H. pylori among young people, and periodic endoscopic examination have been proposed to reduce GC deaths (5) . However, endoscopy is an invasive and costly method that requires special equipment and well-trained personnel to offer reliable diagnosis. Despite all recent developments in molecular diagnostic (16) , identification of biomarkers with reliable predictive value are still unavailable. Peripheral blood mtDNA copy number has recently emerged as a potential preventive/diagnosis biomarker associated with the risk of various cancers (18) , (19) . Levels of circulating mtDNA were found significantly higher in patients with various type of tumors (29) , (30) , (31) , (32) , (44) . Peripheral mtDNA content has also been proposed as a novel molecular marker for tracing tumor progression (34) . In the present study, we found more variation of circulating leukocytes mtDNA level in patients with NAG or GC as compared with healthy subjects. We identify a distribution of samples according to three intervals of mtDNA levels measured as previously described (38) , (40) 
patients. According to these data, by a simple blood sampling, the classification of an individual in intervals I or III would be an indication of the presence of gastric inflammation and probable GC, respectively. This detection would constitute a first indication for the patients, upstream endoscopic investigation and specific follow-up.
In a recent large prospective study, no association between mtDNA copy number and GC was found (35) . However a positive association between low mtDNA copy number and risk of GC was observed in blood collected within the two years prior to cancer diagnosis, suggesting that a decrease in mtDNA level is an early indicator of the malignant transformation of gastritis lesions. In agreement, in our study the lowest mtDNA levels correspond to NAG patients. Gastritis is characterized by a chronic inflammation of the gastric mucosa, associated with high production of oxidative species known to damage DNA, rendering mtDNA highly susceptible to damage and depletion. This is probably the reason for the lower mtDNA levels observed in some NAG cases. Although the role of mtDNA depletion in the cancer process remains unknown, it might decrease mitochondrial genes expression and impair the oxidative phosphorylation chain activity, leading to an increased production of ATP by glycolysis, a mechanism occurring during tumorigenesis, known as the Warburg effect (45) . Low mtDNA copy number has also been reported associated to an increased risk in various cancers (46) to most GC patients. This tendency was observed in Cohort 2 in spite of lower levels of mtDNA in all patients studied, which was probably due to the long time lapse of storage samples before testing. This observation would argue to the importance of using only fresh specimens to have reliable and clinically useful values. It also suggest that mtDNA levels cannot distinguish NAG patients and patients with early pre-neoplastic lesions.
Summarizing results from both cohorts, in healthy H. pylori negative individuals we observed a limited range of mtDNA levels (interval II) and values below this range were found mostly in patients with precancerous stages NAG and IM lesions (interval I); whereas values above this range were observed mostly in patients with GC (interval III). Based on these results and in agreement with a previous study (35) , patients with decreased mtDNA levels potentially represent individuals with increased risk for GC, which should be monitored periodically to effectively prevent GC development. Whereas in patients with increased mtDNA, the presence of GC lesions should be suspected and further tested by endoscopy.
However, in both, precancerous and GC groups we observed patients with mtDNA levels in the same range as healthy individuals. These patients need to be further studied to identify if they represent a group with a different carcinogenesis process or cancer stage. Among GC cases, we noticed a tendency, although not statistically significant, for mtDNA to increase according to the severity of the disease, from patients with hyperplasia or metastasis to laterstage (unresectable). In any case, it should be studied in a larger number of patients, to confirm if mtDNA may help differentiate GC stages and subtypes.
Chronic inflammation contributes to the promotion of cancer. Recently, a positive association has been reported between plasma level of pro-inflammatory cytokines, IL-6 and IL-8, and high GC incidence, suggesting them as potential biomarkers for GC (48) . We did not find any correlation between IL-8 and mtDNA levels, indicating that the inflammatory process does not always drive the observed increased mtDNA levels in GC. In fact, we found on June 20, 2017. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from mostly low IL-8 levels in GC cases with high mtDNA level (interval III). In addition, higher values of IL-8 were detected mostly in GC cases with "normal" mtDNA level (interval II), which supports that determination of both, mtDNA and IL-8, improves the identification of patients with GC in interval II. It is important to notice that most of these GC patients (mtDNA-interval II and IL-8>50 pg/ml) were smokers. MtDNA levels can be also affected by other parameters as infections, that should be taken into account (49) .
In conclusion, we identified three different ranges of peripheral leucocytes mtDNA levels, one present in all healthy H. pylori uninfected subjects and considered as "normal", one with lower mtDNA observed mainly in patients with gastric precancerous lesions and a third increased range corresponding almost exclusively to GC patients. According to our data, quantification of mtDNA by a simple blood sampling would permit an early detection of the presence of lesions and to design a personalized clinical follow-up of patients. Patients with low mtDNA level are likely to present precancerous or GC lesions and should be periodically monitored by endoscopy. Patients with high mtDNA level are more likely to already present GC and should be thoroughly studied by endoscopy. We should notice that there were patients with precancerous and with GC lesions with mtDNA levels in the same range as the asymptomatic group, which deserve more studies. Detection can be improved by testing in addition IL-8 levels, particularly in GC patients that present "normal" mtDNA (interval II).
These data should be further validated in larger patient groups, also including patients from different geographical origin. Our findings indicate that testing for circulating mtDNA and IL-8 might offer reliable minimaly invasive biomarkers, to screen populations at risk for GC.
They pave the way to the development of circulating mtDNA measure as a predictive/earlydiagnostic biomarkers that are particularly needed in developing countries in Asia and Latin America, regions with the highest GC mortality rates. 
